Clinical Trials in Nashville

Showing 3961-3980 of 20,298 trials

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

NCT07218003

The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab. The study is focused on participants with certain solid tumors that are in an advanced stage and have certain tumor makers. This will be done by measuring the side effects that participants experience and how severe they are. Additionally, the study will evaluate how RNDO-564 moves into, through, and out of the body and how the treatment affects the body. The second goal of this study is to evaluate how well RNDO-564 works by itself or in combination with pembrolizumab at treating participants' cancer. This will be done by measuring the number of participants who respond to the treatment. The length of time where the tumor does not grow or spread will also be measured. Participants will take RNDO-564 weekly on Days 1, 8 and 15 of a 21 day cycle. Participants in the combination arms will take RNDO-564 as described with pembrolizumab every 3 weeks.

Non Small Cell Lung CancerCervical CancerHead and Neck Squamous Cell Cancer+7 more

Rondo Therapeutics149 participantsStarted Oct 2025

Huntersville, North Carolina, United States • Nashville, Tennessee, United States

RECRUITINGPhase 2< 1 mile

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

NCT06533826

The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HER2-low or HER2-0) metastatic breast cancer. The names of the study drugs involved in this study are: * Datopotamab deruxtecan (a type of antibody drug conjugate) * Trastuzumab deruxtecan (a type of antibody drug conjugate)

Breast CancerHER2-low Breast CancerMetastatic Breast Cancer+1 more

Ana C Garrido-Castro, MD357 participantsStarted Oct 2024

Birmingham, Alabama, United States • San Francisco, California, United States • New Haven, Connecticut, United States +8 more locations

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Find Trials by Condition in Nashville

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Efficacy and Safety of the CG-100 Intraluminal Bypass Device

A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Minima Stent System Post- Approval Study (PAS)

The Myelin Disorders Biorepository Project

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)

A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

Tissue Reinforcement for Breast Reconstruction (TRBR) Pivotal Clinical Study (REDEFINE)

Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS

Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt

Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH

Radio Frequency (Forma Eye) Treatment for Dry Eye Disease Due to Meibomian Gland Dysfunction